Media stories about Adverum Biotechnologies (NASDAQ:ADVM) have trended positive recently, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Adverum Biotechnologies earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.4597102141761 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Is Adverum Biotechnologies an Incredible Momentum Stock? 3 Reasons Why ADVM Will Be Tough to Beat (finance.yahoo.com)
- Adverum Biotechnologies (ADVM) Presents At 24th Annual NewsMakers in the Biotech Industry – Slideshow (seekingalpha.com)
- Adverum Biotechnologies (ADVM) Names Eric Carter to Board (streetinsider.com)
- Adverum Biotechnologies (ADVM) Names Eric Carter to Board – StreetInsider.com (streetinsider.com)
- Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors (finance.yahoo.com)
ADVM has been the subject of several recent analyst reports. Zacks Investment Research raised Adverum Biotechnologies from a “sell” rating to a “hold” rating in a report on Monday, July 17th. ValuEngine cut Adverum Biotechnologies from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Chardan Capital reissued a “hold” rating and issued a $3.50 price target on shares of Adverum Biotechnologies in a report on Tuesday, September 5th.
Adverum Biotechnologies (NASDAQ:ADVM) remained flat at $3.00 during mid-day trading on Wednesday. 46,379 shares of the company traded hands. The firm’s market capitalization is $129.86 million. Adverum Biotechnologies has a 12-month low of $2.40 and a 12-month high of $4.55. The stock’s 50-day moving average price is $2.59 and its 200-day moving average price is $2.68.
COPYRIGHT VIOLATION NOTICE: “Adverum Biotechnologies (ADVM) Receives News Impact Rating of 0.25” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/09/13/adverum-biotechnologies-advm-receives-news-impact-rating-of-0-25.html.
About Adverum Biotechnologies
Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.
Receive News & Ratings for Adverum Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.